Image: Starpharma
Melbourne-based biotech company, Starpharma, has been slapped with a $93,000 fine for breaching advertising regulations for its new nasal spray, which allegedly had COVID-fighting properties.
The Therapeutic Goods Administration handed down seven infringement notices to Starpharma, totalling $93,200 worth of fines in relation to its Viraleze nasal spray.
“The alleged advertising, on two of Starpharma’s websites, included a restricted representation claiming that Viraleze is an antiviral nasal spray that stops SARS-CoV-2, the virus that causes COVID-19. Any claims or references to preventing or treating a serious form of a disease, condition, ailment or defect are restricted representations,” the TGA said in a statement.
Investegate |Baker Steel Res Tst Announcements | Baker Steel Res Tst: Annual Financial Report
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Oil deal strategic: President - Zimbabwe Situation
zimbabwesituation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zimbabwesituation.com Daily Mail and Mail on Sunday newspapers.